Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
Identifieur interne : 001A93 ( Main/Exploration ); précédent : 001A92; suivant : 001A94Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
Auteurs : Stewart A. Factor [États-Unis] ; Joseph H. Friedman [États-Unis] ; Margaret C. Lannon [États-Unis] ; David Oakes [États-Unis] ; Keith Bourgeois [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2001-01.
English descriptors
- KwdEn :
Abstract
OBJECTIVE: To report the results of the 12‐week, prospective, open label extension of the 4‐week, multicenter, placebo‐controlled, double‐blind PSYCLOPS (PSYchosis and CLOzapine in the treatment of Parkinsonism) trial. This extension examined the chronic safety and efficacy of clozapine in the treatment of drug‐induced psychosis in Parkinson's disease (PD). BACKGROUND: Psychosis is a serious late complication of PD and may be a harbinger to increased mortality. Clozapine, the first atypical antipsychotic, was shown in several small open label studies to improve psychosis without worsening of motor symptoms. This was recently confirmed in the double‐blind PSYCLOPS trial. METHODS: The 53 patients who completed the double‐blind portion of PSYCLOPS were evaluated on their original randomized treatment (clozapine or placebo), then had study medication stopped. All were started on clozapine. The patients from both treatment groups were evaluated every 4 weeks over a 12‐week period using standardized measures for psychosis and PD. RESULTS: The mean dose of clozapine was 28.78 mg/day. Those originally treated with placebo improved significantly in Brief Psychiatric Rating Scale and clinical global scores for psychosis to the same degree as the group originally randomized to clozapine in the double‐blind study. Both groups maintained their response to week 16 (end of the combined double‐blind and open label portions). There was no worsening of motor features as measured by the Unified Parkinson's disease rating scale. Eighteen patients were either hospitalized or died during the trial. The most common reasons were pulmonary. CONCLUSIONS: Low‐dose clozapine is effective in treating drug‐induced psychosis without worsening motor features of PD, and the response is maintained for at least 4 months. Patients with psychosis and PD were previously described as a group with high risk for morbidity and mortality. The high risk continues despite antipsychotic therapy. Mov. Disord. 16:135–139, 2001. © 2001 Movement Disorder Society.
Url:
DOI: 10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name></author><author><name sortKey="Lannon, Margaret C" sort="Lannon, Margaret C" uniqKey="Lannon M" first="Margaret C." last="Lannon">Margaret C. Lannon</name></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name></author><author><name sortKey="Bourgeois, Keith" sort="Bourgeois, Keith" uniqKey="Bourgeois K" first="Keith" last="Bourgeois">Keith Bourgeois</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7C6A64F96D1F129F8EE5A485472A044FC7B6BC90</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q</idno><idno type="url">https://api.istex.fr/document/7C6A64F96D1F129F8EE5A485472A044FC7B6BC90/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">001A87</idno><idno type="wicri:Area/Main/Curation">001828</idno><idno type="wicri:Area/Main/Exploration">001A93</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial</title><author><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Albany Medical College, Albany, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Hospital of Rhode Island, Pawtucket, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Lannon, Margaret C" sort="Lannon, Margaret C" uniqKey="Lannon M" first="Margaret C." last="Lannon">Margaret C. Lannon</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Memorial Hospital of Rhode Island, Pawtucket, Rhode Island</wicri:regionArea><placeName><region type="state">Rhode Island</region></placeName></affiliation></author><author><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bourgeois, Keith" sort="Bourgeois, Keith" uniqKey="Bourgeois K" first="Keith" last="Bourgeois">Keith Bourgeois</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>University of Rochester, Rochester, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-01">2001-01</date><biblScope unit="volume">16</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="135">135</biblScope><biblScope unit="page" to="139">139</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">7C6A64F96D1F129F8EE5A485472A044FC7B6BC90</idno><idno type="DOI">10.1002/1531-8257(200101)16:1<135::AID-MDS1006>3.0.CO;2-Q</idno><idno type="ArticleID">MDS1006</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>clozapine</term><term>psychosis</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">OBJECTIVE: To report the results of the 12‐week, prospective, open label extension of the 4‐week, multicenter, placebo‐controlled, double‐blind PSYCLOPS (PSYchosis and CLOzapine in the treatment of Parkinsonism) trial. This extension examined the chronic safety and efficacy of clozapine in the treatment of drug‐induced psychosis in Parkinson's disease (PD). BACKGROUND: Psychosis is a serious late complication of PD and may be a harbinger to increased mortality. Clozapine, the first atypical antipsychotic, was shown in several small open label studies to improve psychosis without worsening of motor symptoms. This was recently confirmed in the double‐blind PSYCLOPS trial. METHODS: The 53 patients who completed the double‐blind portion of PSYCLOPS were evaluated on their original randomized treatment (clozapine or placebo), then had study medication stopped. All were started on clozapine. The patients from both treatment groups were evaluated every 4 weeks over a 12‐week period using standardized measures for psychosis and PD. RESULTS: The mean dose of clozapine was 28.78 mg/day. Those originally treated with placebo improved significantly in Brief Psychiatric Rating Scale and clinical global scores for psychosis to the same degree as the group originally randomized to clozapine in the double‐blind study. Both groups maintained their response to week 16 (end of the combined double‐blind and open label portions). There was no worsening of motor features as measured by the Unified Parkinson's disease rating scale. Eighteen patients were either hospitalized or died during the trial. The most common reasons were pulmonary. CONCLUSIONS: Low‐dose clozapine is effective in treating drug‐induced psychosis without worsening motor features of PD, and the response is maintained for at least 4 months. Patients with psychosis and PD were previously described as a group with high risk for morbidity and mortality. The high risk continues despite antipsychotic therapy. Mov. Disord. 16:135–139, 2001. © 2001 Movement Disorder Society.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Rhode Island</li><li>État de New York</li></region></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Factor, Stewart A" sort="Factor, Stewart A" uniqKey="Factor S" first="Stewart A." last="Factor">Stewart A. Factor</name></region><name sortKey="Bourgeois, Keith" sort="Bourgeois, Keith" uniqKey="Bourgeois K" first="Keith" last="Bourgeois">Keith Bourgeois</name><name sortKey="Friedman, Joseph H" sort="Friedman, Joseph H" uniqKey="Friedman J" first="Joseph H." last="Friedman">Joseph H. Friedman</name><name sortKey="Lannon, Margaret C" sort="Lannon, Margaret C" uniqKey="Lannon M" first="Margaret C." last="Lannon">Margaret C. Lannon</name><name sortKey="Oakes, David" sort="Oakes, David" uniqKey="Oakes D" first="David" last="Oakes">David Oakes</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001A93 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001A93 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7C6A64F96D1F129F8EE5A485472A044FC7B6BC90
|texte= Clozapine for the treatment of drug‐induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial
}}
| This area was generated with Dilib version V0.6.23. |  |